Table 2 Application of MSCs in treating aGVHD

75

Bone marrow

8[2–17]

ALL: 18

AML: 16

CML: 1

Other: 40

IV

2 × 10⁶

Day + 72

OR: 46 100 day survival: 35

[55]

25

Bone marrow

33 [5–66]

ALL: 9

AML: 8

MDS: 3

Other: 5

III–IV

2 × 10⁶

Day + 2

CR: 6

PR: 9

MR: 4

NC: 1

[56]

26

Bone marrow

6.5 [1–19]

ALL: 8

AML: 5

MDS: 6

Others: 7

III–IV

1.39 × 10⁶

–

CR: 5

PR: 15

No response: 6

[57]

40

Bone marrow

27.8 [1–65]

-

II–IV

1.5 × 10⁶

 < Day + 30 (23)

 > Day + 3 (15)

1 year OS: 50.0%

2 years OS: 38.6%

[58]

35

Bone marrow

7 [0.7–18]

ALL: 10

AML: 6

MDS: 7

JMML: 5

Other: 7

III–IV

2 × 10⁶

Day + 13

CR: 65%

2.9 years OS: 37%

[59]

25

Bone marrow

 < 40 years: 6

40–60 years: 8

 > 60 years: 11

AML: 6

MDS: 7

Other: 12

II–IV

1.1 × 10⁶

–

CR: 11

PR: 6

No response: 7

[60]

14

Bone marrow

52 [4–62]

AML: 4

MDS: 3

ALL: 3

Other: 4

II–III

2 × 10⁶

Day + 25

CR: 8

PR: 5

No response: 1

[61]

50

Bone marrow

19 [1–69]

ALL: 10

AML: 15

Other: 25

II–IV

1.05 × 10⁶

Day + 27

3.6 years OS: 56%

[62]

2

Adipose tissue

15

12

ALL:1

AML:1

III

IV

1 × 10⁶

Day + 68

Day + 97

CR: 12 months

CR: 24 months

[63]

6

Adipose tissue

38 [22–49]

ALL:3

AML:3

III–IV

1 × 10⁶

–

CR: 5

No response: 1

[64]

1

Umbilical cord

4

SAA

IV

3.3 × 10⁶

Day + 13

CR: 18 months

[65]

46

Bone marrow

Adipose tissue

–

–

II–IV

1 × 10⁶

–

OR: 58.7%

2 year survival for responders: 51.85%

[66]